Insider Trading Alert - DTV, TGT, SCG, EXPR And BIIB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 2, 2013, 167 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $696.00 to $31,440,000.00.

Highlighted Stocks Traded by Insiders:

Directv (DTV) - FREE Research Report

Boyd Ralph F Jr who is Director at Directv sold 450 shares at $66.10 on Dec. 2, 2013. Following this transaction, the Director owned 13,313 shares meaning that the stake was reduced by 3.27% with the 450-share transaction.

The shares most recently traded at $65.89, down $0.21, or 0.32% since the insider transaction. Historical insider transactions for Directv go as follows:

  • 4-Week # shares sold: 35,000
  • 12-Week # shares sold: 35,000
  • 24-Week # shares sold: 35,000

The average volume for Directv has been 3.5 million shares per day over the past 30 days. Directv has a market cap of $34.7 billion and is part of the services sector and media industry. Shares are up 31.8% year-to-date as of the close of trading on Monday.

DIRECTV provides digital television entertainment in the United States and Latin America. The company engages in acquiring, promoting, selling, and distributing digital entertainment programming primarily through satellite to residential and commercial subscribers. The company has a P/E ratio of 12.8. Currently there are 12 analysts that rate Directv a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DTV - FREE

TheStreet Quant Ratings rates Directv as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Directv Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Target (TGT) - FREE Research Report

Fisher Anthony S. who is Executive Officer at Target sold 4,415 shares at $63.93 on Dec. 2, 2013. Following this transaction, the Executive Officer owned 0 shares meaning that the stake was reduced by 100% with the 4,415-share transaction.

The shares most recently traded at $62.89, down $1.04, or 1.65% since the insider transaction. Historical insider transactions for Target go as follows:

  • 24-Week # shares sold: 2,277

The average volume for Target has been 4.5 million shares per day over the past 30 days. Target has a market cap of $40.4 billion and is part of the services sector and retail industry. Shares are up 6.02% year-to-date as of the close of trading on Monday.

Target Corporation operates general merchandise stores in the United States. The stock currently has a dividend yield of 2.69%. The company has a P/E ratio of 17.2. Currently there are 5 analysts that rate Target a buy, 2 analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TGT - FREE

TheStreet Quant Ratings rates Target as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Target Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

SCANA (SCG) - FREE Research Report

Mcfadden Charles B who is Senior VP SCANA/SCANA Srvcs at SCANA sold 20,000 shares at $47.27 on Dec. 2, 2013. Following this transaction, the Senior VP SCANA/SCANA Srvcs owned 21,520 shares meaning that the stake was reduced by 48.17% with the 20,000-share transaction.

The shares most recently traded at $47.24, down $0.03, or 0.07% since the insider transaction.

The average volume for SCANA has been 730,900 shares per day over the past 30 days. SCANA has a market cap of $6.6 billion and is part of the utilities sector and utilities industry. Shares are up 3.09% year-to-date as of the close of trading on Monday.

SCANA Corporation, through its subsidiaries, engages in the generation, transmission, distribution, and sale of electricity to retail and wholesale customers in South Carolina. It owns nuclear, coal, hydro, oil and gas, and biomass generating facilities. The stock currently has a dividend yield of 4.3%. The company has a P/E ratio of 13.7. Currently there are 3 analysts that rate SCANA a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCG - FREE

TheStreet Quant Ratings rates SCANA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, growth in earnings per share, notable return on equity and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full SCANA Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Express (EXPR) - FREE Research Report

Kornberg David G who is President at Express sold 6,000 shares at $24.49 on Dec. 2, 2013. Following this transaction, the President owned 169,685 shares meaning that the stake was reduced by 3.42% with the 6,000-share transaction.

Historical insider transactions for Express go as follows:

  • 4-Week # shares sold: 8,571
  • 12-Week # shares sold: 123,377
  • 24-Week # shares sold: 216,247

The average volume for Express has been 819,900 shares per day over the past 30 days. Express has a market cap of $2.1 billion and is part of the services sector and retail industry. Shares are up 61.96% year-to-date as of the close of trading on Monday.

Express, Inc. operates as a specialty apparel and accessory retailer primarily in the United States. Its stores provide apparel and accessories for women and men between 20 and 30 years old across various aspects of the lifestyles comprising work, casual, jeanswear, and going-out occasions. The company has a P/E ratio of 16.1. Currently there are 7 analysts that rate Express a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXPR - FREE

TheStreet Quant Ratings rates Express as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Express Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biogen Idec (BIIB) - FREE Research Report

Schenk Lynn who is Director at Biogen Idec sold 1,000 shares at $291.71 on Dec. 2, 2013. Following this transaction, the Director owned 4,100 shares meaning that the stake was reduced by 19.61% with the 1,000-share transaction.

The shares most recently traded at $291.51, down $0.20, or 0.07% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 2,239
  • 12-Week # shares sold: 10,319
  • 24-Week # shares sold: 21,404

The average volume for Biogen Idec has been 1.2 million shares per day over the past 30 days. Biogen Idec has a market cap of $68.7 billion and is part of the health care sector and drugs industry. Shares are up 98.79% year-to-date as of the close of trading on Monday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 40.9. Currently there are 13 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec